Form 4: Director Arnold J. Levine Receives PMVP Stock Options

Director Arnold J. Levine was granted 42,000 stock options in PMV Pharmaceuticals, Inc. on June 4, 2026.

Summary

• Director Arnold J. Levine acquired 42,000 stock options in PMV Pharmaceuticals, Inc. (PMVP).
• The options have an exercise price of $1.19 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in nature.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $1.19 may be subject to market fluctuations relative to the future trading price of PMVP.

Future Outlook

The options vest on the earlier of June 4, 2027, or the date of the Issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common practice for board members in the U.S. life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 4, 2027, or the next annual meeting date.

Key Dates

Keywords

PMVP, PMV Pharmaceuticals, Form 4, Insider Trading, Stock Options, Director Compensation